Lipid disorders in type 2 diabetes

Endocrinologia y Nutricion

Volumn 56, Issue SUPPL. 4, 2009, Pages 43-45

  Laakso, Markku ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK REDUCTION; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MULTICENTER STUDIES AS TOPIC; PROCETOFEN; RISK FACTORS;

EID: 77953272214     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/S1575-0922(09)73517-X     Document Type: Article

References (12)

1. Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
2. Laakso M., and Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev 5 (1997) 294-315
3. Laakso M. Epidemiology of diabetic dyslipidemia. Diabetes Rev 3 (1995) 408-422
4. Mazzone T., Chait A., and Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 371 (2008) 1800-1809
5. Turner R.C., Millns H., Neil H.A., Stratton I.M., Manley S.E., Matthews D.R., et al. for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 316 (1998) 823-828
6. Lehto S., Rönnemaa T., Haffner S.M., Pyörälä K., Kallio V., and Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 48 (1997) 1354-1359
7. Adiels M., Olofsson S.O., Taskinen M.R., and Boren J. Overproductionof very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thomb Vasc Biol 28 (2008) 1225-1236
8. Adiels M., Taskinen M.R., Packard C., Caslake M.J., Soro-Paavonen A., Westerbacka J., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49 (2006) 755-765
9. Austin M.A., King M.-.C., Vranizan K.M., and Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82 (1990) 495-506
10. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al., for Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
11. Kearney P.M., Blackwell L., Collins R., Keech A., Simes R., Peto R., et al., For the Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008) 117-125
12. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861